An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2) (VENUS-2)

An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV

To investigate the maximum tolerated dose of BIBF 1120 and safety in escalating doses administered with Vinorelbine i.v. and Carboplatin i.v. in elderly patients with advanced Non-Small Lung Cancer (Stage IV).

Study Overview

• Status: Completed
• Conditions: Carcinoma, Non-Small-Cell Lung
• Intervention / Treatment: Drug: BIBF 1120; Drug: Vinorelbine; Drug: Carboplatin

Detailed Description

Patients older than 70 years could be enrolled in this clinical trial. The trial is being carried out in two trial centres in Germany.

For the planned sample size it is assumed that two different dosage groups are needed with 6 patients on each dosage group with the option to deescalate the first dosage. Altogether this leads to an estimated sample size of maximal 18 patients.

• Duration of treatment/patient: up to 6 month
• Follow Up: at least 6 month

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 1

Contacts and Locations

Study Locations

• Germany
  • Großhansdorf, Germany, D-22927
    • Krankenhaus Großhansdorf
  • Kassel, Germany, D-34125
    • Klinikum Kassel Gmbh

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 69 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histological confirmed Non-Small-Cell lung cancer (NSCLC)
• Tumor stage IV (UICC 7th Version)
• ECOG <2
• Age > 70 years
• No previous chemotherapy for stage IV NSCLC (UICC 7th Version)
• Adjuvant or neoadjuvant chemotherapy for NSCLC must be completed at least one year prior to study enrolment (from end of chemotherapy)

• Patients with prior radiation therapy may be eligible for this study if they meet the following guidelines:

  • Previous radiation therapy is allowed to <25% of the bone marrow (Cristy and Eckerman 1987), but should have been limited and must not have included whole pelvis radiation.
  • Patients must have recovered from the toxic effects of the treatment prior to study enrolment (except for alopecia).
  • Prior thoracic radiotherapy must be completed 30 days before study enrolment.
  • Lesions that have been irradiated cannot be included as sites of measurable disease unless clear tumour progression has been documented in these lesions since the end of radiation therapy.
  • Palliative extrathoracic radiotherapy to pre-existing lesions may continue on study; however, these lesions may not be included as sites of measurable disease.

• Adequate haematological laboratory parameters:

  • Haemoglobin ≥9 g/dl
  • WBC ≥3.000/µl
  • Platelets ≥ 100.000/µl
  • Neutrophil count > 1,500/µl

• Adequate renal laboratory parameters

  • Creatinine ≤1,9 mg/dl
  • Creatinine Clearance > 45 ml/min

• Adequate hepatic function

  • Total bilirubin within normal range
  • Total bilirubin < 1.5 x ULN (patients with liver metastasis)
  • ALT < 1.5 x ULN
  • ALT < 2.5 x ULN (patients with liver metastasis)
  • AST < 1.5 x ULN
  • AST < 2.5 x ULN (patients with liver metastasis)
  • Alk. phosphatase < 3 x ULN
  • LDH < 5 x ULN ULN = Upper Limit Of Normal (ULN)

• Other lab parameters:

  • Proteinuria < CTCAE grade 2
  • Prothrombin time and/or partial thromboplastin time < 50 % deviation from normal limits
• Informed consent, personally signed and dated to participate in the study
• Male patients enrolled in this trial must use adequate barrier birth control measures during the course of treatment and for at least 3 months after the last administration of study therapy
• Life expectancy at least 3 months

Exclusion Criteria:

• Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardise compliance with the protocol
• Serious infections requiring systemic antibiotic (e.g antiviral, antimicrobial, antifungal) therapy
• Serious, non-healing wound, ulcer or bone fracture or major injuries and/or surgery within 4 weeks of trial inclusion, or planned surgical procedures during the trial period.
• Investigational drug therapy outside of this trial during or within 4 weeks of study entry
• Known hypersensitivity to the trial drugs or their excipients.
• History of other malignancies in the last 5 years, in particular those which could affect compliance with the protocol or interpretation of results. Patients with adequately treated basal or squamous cell skin cancer are generally eligible.
• Serious concomitant disease, especially those that would limit compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
• Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 9 months, congestive heart failure >NYHA II)
• Known inherited predisposition to bleeds or to thrombosis.
• Patient with brain metastases that are symptomatic and/or require therapy.
• Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid ≤ 325mg per day)
• History of major thrombotic events or clinically relevant major bleeding event in the past 6 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis below the joint space of the knee)
• Current peripheral neuropathy ≥ CTCAE grade 2 except due to trauma
• Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
• Active alcohol or drug abuse.
• Men who are sexually active and unwilling to use a medically acceptable method of contraception
• Leptomeningeal disease
• Radiographic evidence of cavitary or necrotic tumours
• Centrally located tumours with radiographic evidence (CT or MRI) of local invasion of major blood vessels

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BIBF 1120, Vinorelbine, Carboplatin; To determine the 'Maximum Toleraetd Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle. Under certain conditions the dose level will be escalated to 200mg bid in a second cohort.	Drug: BIBF 1120; 2 x 150 mg capsules, oral, daily (Start dose); Drug: Vinorelbine; 25 mg/m2 i.v. on day 1 and 8 (three-week cycle); Drug: Carboplatin; AUC 5 i.v. on day 1 (three-week cycle)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To investigate the maximum tolerated dose of BIBF 1120	Cycle 1 day 1, day 8, day 15; Cycle 2 day 1, day 8, day 15; Cycle 3 day 1, day 8, day 15; Cycle 4 day 1, day 8, day 15; day 84

Secondary Outcome Measures

Outcome Measure	Time Frame
Incidence of adverse events	Cycle 1 day 1, day 8, day 15; Cycle 2 day 1, day 8, day 15; Cycle 3 day 1, day 8, day 15; Cycle 4 day 1, day 8, day 15; day 84
Response Rate	Day 43 (prior start of cycle 3), day 84

Collaborators and Investigators

• Sponsor: Aktion Bronchialkarzinom e.V.
• Collaborators: Boehringer Ingelheim
• Investigators: Principal Investigator: Prof. Dr. Martin Wolf, MD, Klinikum Kassel GmbH, D-34125 Kassel; Study Chair: Prof. Dr. Rudolf M. Huber, MD, Klinikum der Universität München, D-80336 München

Study record dates

Study Major Dates

• Study Start: April 1, 2013
• Primary Completion (Actual): January 1, 2015

Study Registration Dates

• First Submitted: August 28, 2012
• First Submitted That Met QC Criteria: September 10, 2012
• First Posted (Estimate): September 12, 2012

Study Record Updates

• Last Update Posted (Estimate): January 26, 2015
• Last Update Submitted That Met QC Criteria: January 22, 2015
• Last Verified: January 1, 2015

More Information

Terms related to this study

• Keywords: NSCLC Stage IV; Non-Small Lung Cancer
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Protein Kinase Inhibitors; Carboplatin; Nintedanib; Vinorelbine
• Other Study ID Numbers: ABC-2011-NSCLC-04; 2011-002141-36 (EudraCT Number)